Change 5-day change 1-year change 3-year change Capi.($)
+1.12%-1.04% - - 16.15M
-3.30%+1.50%+57.79%+85.24% 72.26B
+1.25%-3.01%+37.83%+84.34% 60.24B
+2.12%+5.26%+35.69%+18.97% 27.73B
-3.06%-1.81%-14.01%+354.94% 25.73B
-0.75%+2.56%+0.45%-4.46% 24.75B
+0.40%+0.75%+23.72%-9.50% 20.74B
-1.70%-2.12%+150.24%+323.16% 15.06B
+0.36%-0.34%+48.98%+162.10% 14.41B
+0.21%+1.17%-3.95%+484.12% 14.23B
Average -0.34%+0.44%+37.41%+166.54% 30.57B
Weighted average by Cap. -0.77%+0.31%+38.16%+126.05%
Logo Opexa Therapeutics Inc
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Employees
-